CN114699343A - Phellinus linteus fermentation product and preparation method thereof - Google Patents
Phellinus linteus fermentation product and preparation method thereof Download PDFInfo
- Publication number
- CN114699343A CN114699343A CN202210049751.7A CN202210049751A CN114699343A CN 114699343 A CN114699343 A CN 114699343A CN 202210049751 A CN202210049751 A CN 202210049751A CN 114699343 A CN114699343 A CN 114699343A
- Authority
- CN
- China
- Prior art keywords
- fermentation
- fomes fomentarius
- fomes
- fomentarius
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 97
- 230000004151 fermentation Effects 0.000 title claims abstract description 97
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 241000001727 Tropicoporus linteus Species 0.000 title description 3
- 241000123330 Fomes fomentarius Species 0.000 claims abstract description 63
- 239000000047 product Substances 0.000 claims abstract description 43
- 244000061456 Solanum tuberosum Species 0.000 claims abstract description 41
- 235000002595 Solanum tuberosum Nutrition 0.000 claims abstract description 41
- 239000000758 substrate Substances 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 16
- 230000001954 sterilising effect Effects 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 5
- 230000003213 activating effect Effects 0.000 claims abstract description 4
- 239000006228 supernatant Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 235000012015 potatoes Nutrition 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 30
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 29
- 230000008439 repair process Effects 0.000 abstract description 15
- 239000002537 cosmetic Substances 0.000 abstract description 9
- 239000011049 pearl Substances 0.000 description 50
- 102000003777 Interleukin-1 beta Human genes 0.000 description 33
- 108090000193 Interleukin-1 beta Proteins 0.000 description 33
- 238000011081 inoculation Methods 0.000 description 18
- 238000010586 diagram Methods 0.000 description 16
- 238000001514 detection method Methods 0.000 description 15
- 102000003425 Tyrosinase Human genes 0.000 description 14
- 108060008724 Tyrosinase Proteins 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 108090001007 Interleukin-8 Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 230000002087 whitening effect Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229960004441 tyrosine Drugs 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000123326 Fomes Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- PGNRLPTYNKQQDY-UHFFFAOYSA-N 2,3-dihydroxyindole Chemical compound C1=CC=C2C(O)=C(O)NC2=C1 PGNRLPTYNKQQDY-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000222383 Polyporales Species 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 241001556385 Sanghuangporus baumii Species 0.000 description 1
- 241000712689 Velutina Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present disclosure provides a preparation method of fomes fomentarius fermentation product, comprising: step one, activating, purifying and carrying out enlarged culture on fomes fomentarius to obtain seed liquid; inoculating the seed liquid to a fermentation substrate for fermentation culture treatment to obtain fermentation liquid; the fermentation substrate is potato homogenate; and step three, performing separation treatment and sterilization treatment on the fermentation liquor to obtain supernatant. Also disclosed are the resulting fomes fomentarius fermentates, including fomes fomentarius fermentation broth and dry powder thereof. In the preparation method of the fomes fomentarius fermentation product, fomes fomentarius is inoculated into the potato homogenate for fermentation, and the obtained fermentation product has good skin anti-inflammatory protection and repair effects and can be added into a cosmetic formula as an effective component.
Description
Technical Field
The disclosure belongs to the technical field of biological fermentation, and particularly relates to fomes fomentarius fermentation products and a preparation method thereof.
Background
Fomes fomentarius (Latin name is Fomes fomentarius), also called Fomes velutina, belonging to the class of Basidiomycetes, order of Polyporales, family of Polyporaceae, genus Fomes, is a white rot fungus, usually parasitized on broad-leaved trees such as birch, poplar, pear, apple, etc., and its fruit body is medicinal part, and can be used for removing food retention and removing blood stasis. Fomes fomentarius is a fungus with important application value, the sporocarp and the hypha of the fomes fomentarius contain various substances with biological activity, the representative substance is fomes fomentarius polysaccharide, and the polysaccharide is proved by Chinese and foreign medical research results to have the effects of resisting oxidation, promoting urination, reducing fever, relieving pain, diminishing inflammation, resisting tumors and the like.
However, reports on the application of fomes fomentarius to cosmetics are still blank at present. The inventor finds that the fermentation product obtained by the synergistic fermentation of fomes fomentarius and pearl has excellent skin anti-inflammatory repair effect and whitening effect, and can be used as an effective component for cosmetics.
Disclosure of Invention
The following presents a simplified summary of the disclosure in order to provide a basic understanding of some aspects of the disclosure. It should be understood that this summary is not an exhaustive overview of the disclosure. It is not intended to identify key or critical elements of the disclosure or to delineate the scope of the disclosure. Its sole purpose is to present some concepts in a simplified form as a prelude to the more detailed description that is discussed later.
In order to solve the technical problem, the technical scheme provided by the disclosure is as follows:
in a first aspect, the present disclosure provides a method for preparing a fomes fomentarius ferment, comprising:
step one, activating, purifying and carrying out enlarged culture on fomes fomentarius to obtain seed liquid;
inoculating the seed liquid to a fermentation substrate for fermentation culture treatment to obtain fermentation liquid; the fermentation substrate is potato homogenate;
and step three, performing separation treatment and sterilization treatment on the fermentation liquor to obtain supernatant.
Further, in the preparation method of the fomes fomentarius fermented product, pearl powder is also added into the fermentation substrate; the pearl powder content is 1-10 wt% (such as 2 wt%, 3 wt%, 4 wt%, 5 wt%, 6 wt%, 7 wt%, 8 wt%, 9 wt% etc.) of the potato homogenate; more preferably 1 to 5 wt% (e.g., 1.5 wt%, 2 wt%, 3 wt%, 4 wt%, 4.5 wt%, etc.).
Further, in the above method for producing a fomes fomentarius fermented product, the potato homogenate is obtained by homogenizing fresh cut potatoes with water by a homogenizer and dissolving, wherein the content of the potatoes is 1 to 5 wt% (e.g., 1.2 wt%, 1.5 wt%, 2.0 wt%, 2.5 wt%, 3 wt%, 3.5 wt%, 4 wt%, 4.5 wt%, etc.).
Further, in the above method for preparing fomes fomentarius fermented product, the potato homogenate further comprises 0.3 wt% of monopotassium phosphate, 0.15 wt% of magnesium sulfate, 0.05 wt% of glucose, and 0.2 wt% of soybean peptide.
The fermentation substrate is subjected to conventional sterilization treatment, such as high temperature sterilization at 115 ℃ for 20min, before inoculation.
Further, in the above method for producing a fomes fomentarius fermented product, the seed liquid has a hypha volume percentage of 80% or more (for example, 82%, 85%, 90%, etc.); the inoculation proportion of the Phellinus baumii, namely the volume ratio of the bacteria liquid to the pearl liquid fermentation medium (fermentation substrate) is 1-10% (such as 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, etc.).
Further, the fomes fomentarius is purchased from China general microbiological culture Collection center and is selected from at least one of the following: CGMCC5.1494, CGMCC 5.983, GCMCC5.96 or GCMCC 5.913.
Further, in the above method for preparing fomes fomentarius fermentation product, the temperature of the fermentation culture treatment is 25-35 deg.C (such as 26 deg.C, 28 deg.C, 30 deg.C, 32 deg.C, 34 deg.C, etc.), and the time is 48-96h (such as 52h, 60h, 72h, 84h, 88h, 92h, etc.).
Further, the fermentation culture process is carried out in a shaker at a speed of 150r/min to 200r/min (e.g., 155r/min, 160r/min, 165r/min, 170r/min, 180r/min, 190r/min, 195r/min, etc.).
Further, in the above method for producing a fomes fomentarius fermented product, the separation treatment is performed by a centrifugation method; more preferably, the centrifugation speed is 4500r/min-5500r/min (such as 4600r/min, 4800r/min, 5000r/min, 5200r/min, 5400r/min, etc.), and the centrifugation time is 10min-20min (such as 12min, 15min, 18min, etc.).
In a second aspect, the present disclosure provides a fomes fomentarius ferment obtained by the above preparation method. The fermentation product of fomes fomentarius Margarita comprises fomes fomentarius fermentation liquid and dry powder thereof, and the dry powder can be prepared by freeze drying or spray drying.
In a third aspect, the present disclosure also provides a cosmetic containing the fomes fomentarius fermentation product. The cosmetic may be facial mask, essence, cream, lotion, etc.
Compared with the prior art, the beneficial effects of the present disclosure include but are not limited to:
1. the fomes fomentarius fermentation product is prepared by inoculating fomes fomentarius into potato homogenate for fermentation, and the obtained fermentation product has good skin anti-inflammatory protection and repair effects;
2. according to the preparation method of the fomes fomentarius fermentation product, the fomes fomentarius and the pearls are subjected to synergistic fermentation to prepare the fermentation product with excellent anti-inflammatory performance and whitening performance, and the fermentation product can be used as an effective component to be added into a cosmetic formula to prepare cosmetics such as a facial mask, essence, sunscreen cream and emulsion;
3. the fomes fomentarius fermentation product provided by the disclosure as a cosmetic efficacy component has the characteristics of strong efficacy, low cost, simple operation, green safety and the like, and has strong practicability and popularization value.
Drawings
FIG. 1 is a schematic diagram of the anti-inflammatory effect detection result of the protection treatment of the fomes fomentarius pearl fermentation product in example 2, and indexes are as follows: IL-1 β;
fig. 2 is a schematic diagram of the anti-inflammatory effect test results of the protection treatment of the pearl potato extract in example 2, with the following indexes: IL-1 β;
FIG. 3 is a schematic diagram of the protection treatment anti-inflammatory effect detection results of different concentrations of fomes fomentarius pearl fermentation in example 2, and the indexes are as follows: IL-1 β;
FIG. 4 is a schematic diagram of the detection result of the anti-inflammatory effect of the restoration treatment of the fomes fomentarius pearl fermentation product in example 2, and the indexes are as follows: IL-1 β;
fig. 5 is a schematic diagram of the detection result of the repair treatment anti-inflammatory effect of the pearl potato extract in example 2, and indexes are as follows: IL-1 β;
FIG. 6 is a schematic diagram of the detection results of the repair treatment anti-inflammatory effect of the fomes fomentarius pearl fermentation products with different concentrations in example 2, and the indexes are as follows: IL-1 β;
fig. 7 is a schematic diagram of the detection result of the repair treatment anti-inflammatory effect of the pearl and potato extract in example 2, and the indexes are as follows: IL-8;
FIG. 8 is a schematic diagram of the detection results of the repair treatment anti-inflammatory effect of the fomes fomentarius pearl fermentation products with different concentrations in example 2, and the indexes are as follows: IL-8.
Detailed Description
The following examples further illustrate the present invention but are not to be construed as limiting the invention. Modifications or substitutions to methods, steps or conditions of the present invention may be made without departing from the spirit and scope of the invention.
The technical solutions of the present disclosure will be described below with reference to exemplary embodiments. The experimental procedures used in the following examples are all conventional procedures unless otherwise specified. Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
The fomes fomentarius used in the examples is a commercial product purchased from China general microbiological culture Collection center with the preservation numbers: CGMCC 5.1494.
Example 1 preparation of Phellinus linteus fermentation product
(1) Activating strains: selecting a colony from a preserved fomes fomentarius CGMCC5.1494 (laboratory number 5372) inclined plane, culturing the colony in a glucose potato agar culture medium at 28 ℃ for 7d for activation, then inoculating the obtained single colony to 100mL of glucose potato liquid culture medium, culturing at 28 ℃ and 180rpm for 7d to obtain fomes fomentarius seed liquid, wherein the volume ratio of mycelium accounts for 80% of the whole seed liquid.
(2) Preparing a fermentation substrate: according to the settings of the following table 1, a certain mass ratio of pearl powder (1-10 wt%, such as 1 wt%, 5 wt%, 10 wt%) is added to potato homogenate, wherein the potato homogenate is prepared by adding 1000ml of mineral water (containing 0.3% of potassium dihydrogen phosphate, 0.15% of magnesium sulfate, 0.05% of glucose, 0.2% of soybean peptide) into 20g of cut potatoes, homogenizing, dissolving, and packaging. The fermentation substrate is sterilized prior to inoculation.
(3) Inoculating and shaking bacteria: according to the inoculation amount of 5 percent by volume, 5mL of the seed solution is inoculated into a 250mL triangular flask containing 100mL of fermentation substrate, and the mixture is fermented in a shaking table at the rotating speed of 180r/min, the culture temperature of 28 ℃ and the fermentation time of 48 h.
(4) Centrifuging: centrifuging the fermentation broth at 4800r/min for 10min, collecting supernatant, and sterilizing to obtain sample numbers shown in Table 1.
In this example, a control group was also provided, and the simple fermentation substrate was the above-mentioned 2% potato homogenate to which 0.3% monopotassium phosphate, 0.15% magnesium sulfate, 0.05% glucose, and 0.2% soybean peptide were added. See table 1 for details.
TABLE 1 fermentation System and Experimental group designations for example 1
Number of experimental group | Fermentation substrate | Inoculation situation |
TD-0 | Substrate for simple fermentation | Without inoculation |
TD-5372 | Substrate for simple fermentation | Inoculation of 5372 |
1%ZZ-TD-5372 | Fermentation substrate containing 1% of pearl powder | Inoculation of 5372 |
5%ZZ-TD-5372 | Fermentation substrate containing 5% of pearl powder | Inoculation of 5372 |
10%ZZ-TD-5372 | Fermentation substrate containing 10% of pearl powder | Inoculation of 5372 |
1%ZZ-TD | Fermentation substrate containing 1% of pearl powder | Without |
5%ZZ-TD | Fermentation substrate containing 5% of pearl powder | Without |
10%ZZ-TD | Fermentation substrate containing 10% of pearl powder | Without inoculation |
The main components of the product prepared in example 1, including protein, amino acid and calcium content, were measured, and the results are shown in tables 2 to 4 below.
TABLE 2 amino acid content (umol/mL) of the stock solution or fermentation stock solution samples
TABLE 3 protein content (ug/mL) of the stock or fermentation stock samples
TABLE 4 calcium content of stock solution or fermentation stock solution
Number of experimental group | Calcium (mg/kg) | Number of experimental group | Calcium (mg/kg) |
TD-0 | 12.4 | TD-5372 | 1.3 |
1%ZZ-TD | 39.0 | 1%ZZ-TD-5372 | 179.5 |
5%ZZ-TD | 33.1 | 5%ZZ-TD-5372 | 167.7 |
10%ZZ-TD | 28.2 | 10%ZZ-TD-5372 | 25.3 |
Example 2 efficacy analysis of fomes fomentarius fermentate
Toxicity and protective action of fomes fomentarius fermentation product on human skin fibroblast (HSF cell)
1. Establishment of oxidative stress model
HSF cells were plated at 1X 10 per well4Inoculating into 96-well plate, culturing overnight in cell culture box, discarding culture medium, and adding 100 μ L of different concentrations of H2O2(50~1000μmol·L-1) The culture medium of (1) was repeated 5 times for each group, and no H was added to the control group2O2. After 1, 2, 3, 4h of stimulation, the OD of each well was measured at 490nm using the MTT method. The survival rate of HSF cells (see figure 1) is obtained, and the hydrogen peroxide concentration with the cell survival rate of 50% is selected as the modeling concentration. In this example, 100. mu. mol. L-1H of (A)2O2The HSF cells are treated for 2h for modeling, and the cell survival rate is (49.74 +/-2.99)%.
2. Sample pair H2O2Protection and repair testing of induced oxidative stress model
Refining HSFCells at 1X 10 per well4Each of the cells was inoculated in a 96-well plate and cultured overnight in a cell incubator, and a blank Control group (Control), a Model group (Model), and each sample group (stock solution or fermentation stock solution in example 1) were set for each experiment, and 3 replicates were set for each group.
The detection of the repairing effect means that after the cells are damaged, the samples are used for acting, and whether the samples have the repairing effect is evaluated by measuring the content of IL-1 beta and the like. The repair treatment group in this embodiment: adding H first2O2After 2h of stimulation, 100 mu L of sample is added into each hole for culturing for 24 h;
and (3) protective effect detection, namely, after the sample acts on the cells, damaging the cells again, observing isosecretion conditions of IL-1 beta of the cells, and judging whether the sample has a protective effect. Protection processing group in this embodiment: adding the sample to culture for 24H, and adding H2O2And stimulating for 2 hours.
Testing indexes are as follows: IL-1. beta. and IL-8 (test method refers to kit instructions). The results are shown in FIGS. 1-8.
FIG. 1 is a schematic diagram of the anti-inflammatory effect test results of the protection treatment of fomes fomentarius fermentation product in example 2, and the indexes are as follows: IL-1 beta. As can be seen from the figure, IL-1 beta of the Model group (Model) is extremely higher than that of the blank Control group (Control), which indicates that the Model is successfully established; compared with the model group, the 1% ZZ-TD has no significant difference, and after inoculation and fermentation, the 1% ZZ-TD-5372 is extremely lower than the model group, which shows that the fermentation liquor after inoculation is helpful to reduce the secretion of IL-1 beta and has anti-inflammatory effect.
Fig. 2 is a schematic diagram of the anti-inflammatory effect test results of the protection treatment of the pearl potato extract in example 2, with the following indexes: IL-1 beta. From the figure, the IL-1 beta of the model group is remarkably higher than that of the blank control group, which shows that the model is successfully established, and the influence change difference of the pearl and potato extracts with different proportions on the IL-1 beta is large. When the pearl proportion is 0, the effect of IL-1 beta is not reduced, which shows no anti-inflammatory effect, the pearl potato extract added with 1% -5% of pearl powder has extremely obvious effect of reducing IL-1 beta, which shows anti-inflammatory effect, and when the pearl proportion is increased to 10%, the influence on IL-1 beta is not obviously different, and the pearl potato extract does not have anti-inflammatory effect.
FIG. 3 is a schematic diagram of the protection treatment anti-inflammatory effect detection results of different concentrations of fomes fomentarius pearl fermentation in example 2, and the indexes are as follows: IL-1 beta. The graph shows that the IL-1 beta of the model group is remarkably higher than that of the blank control group, which indicates that the model is successfully established, 5372 the fermentation product inoculated into the potato culture medium without pearl addition can also remarkably reduce the secretion of the IL-1 beta and has anti-inflammatory effect; when 1-5% of pearls are added according to the proportion, the anti-inflammatory effect is more obvious; but inoculation of 5372 when added to 10% pearls is not able to reduce IL-1 β.
FIG. 4 is a schematic diagram of the detection result of the anti-inflammatory effect of the restoration treatment of the fomes fomentarius pearl fermentation product in example 2, and the indexes are as follows: IL-1 beta. It can be seen from the figure that the IL-1 beta of the model group is significantly higher than that of the blank control group, which indicates that the model is successfully established, and compared with the effects on the IL-1 beta of the potato extract with the same pearl addition ratio before and after fermentation, the fermentation product after inoculation of 5372 has significant effect of reducing the IL-1 beta, but does not have the effect of reducing the IL-1 beta before fermentation.
Fig. 5 is a schematic diagram of the detection result of the repair treatment anti-inflammatory effect of the pearl and potato extract in example 2, and the indexes are as follows: IL-1 beta. From the figure, the IL-1 beta of the model group is extremely higher than that of the blank control group, which indicates that the model is successfully established; the pearl potato extract with 5% of pearl addition rate has repairing effect, while the pearl potato extract with 1% of pearl addition rate and 10% of pearl addition rate has no reduction effect on IL-1 beta.
FIG. 6 is a schematic diagram of the detection results of the repair treatment anti-inflammatory effect of the fomes fomentarius pearl fermentation products with different concentrations in example 2, and the indexes are as follows: IL-1 beta. From the figure, the IL-1 beta of the model group is extremely higher than that of the blank control group, which represents that the model is successfully established; the secretion of IL-1 beta cannot be reduced in the potato culture medium without pearl addition before or after fermentation, and the potato culture medium has no anti-inflammatory repair effect; when 1-5% of pearls are added according to the proportion, the anti-inflammatory repair effect is obvious; however, inoculation of 5372 fermentation product when added to 10% pearls is not able to reduce IL-1 β.
Fig. 7 is a schematic diagram of the detection result of the repair treatment anti-inflammatory effect of the pearl and potato extract in example 2, and the indexes are as follows: IL-8. From the figure, it can be seen that the IL-8 in the model group is extremely higher than that in the blank control group, which indicates that the model is successfully established; the pearl-potato extract with 10% of pearl addition has IL-8 reducing effect, i.e. repairing effect, but the potato extract with 1% and 5% of pearl addition has no anti-inflammatory effect.
FIG. 8 is a schematic diagram of the detection results of the repair treatment anti-inflammatory effect of the fomes fomentarius pearl fermentation products with different concentrations in example 2, and the indexes are as follows: IL-8. As can be seen from the figure, the IL-8 in the model group is extremely higher than that in the blank control group, which indicates that the model is successfully established; the 5372 potato fermentation liquor without pearl has IL-8 reducing effect, which indicates that the potato fermentation liquor has repairing effect; the potato fermentation liquor with the pearl addition amount of 1-5% also has the effect of reducing IL-8, which shows that the potato fermentation liquor has a repairing effect; when the addition was increased to 10%, there was no repairing effect (no significant effect on IL-8).
Second, the tyrosinase inhibitory activity test of fomes fomentarius fermentation product
1. Principle of experiment
The formation of melanin is that tyrosine in skin melanocyte tissue is gradually converted into true melanin through intermediates such as dopa, dopaquinone, dopachrome and dihydroxyindole under the action of enzymes such as tyrosinase and the like; furthermore, melanin is transferred into keratin cells by melanocyte tissues and is shed along with the turnover of the stratum corneum, and the difference of human skin color mainly depends on the content and distribution of the true melanin and the pheomelanin, but when the true melanin is excessively increased and unevenly distributed, local skin hyperdarkening or pigmentation is caused. There are three major enzymes involved in melanin synthesis: tyrosinase, dopachrome tautomerase and dihydroxyindole carboxylate oxidase. Tyrosinase belongs to oxidoreductase and is the main rate-limiting enzyme for melanin synthesis, the activity of the oxidoreductase determines the formation amount of melanin, and many whitening and freckle-removing products sold on the market achieve the whitening effect by inhibiting the activity of tyrosinase, so the strength of the inhibition effect on the tyrosinase is the main index for evaluating whitening cosmetics. The L-tyrosinase and its substrate L-tyrosine can be reacted catalytically. After a reagent with the L-tyrosinase activity inhibition effect is added into an experimental system, the inhibition effect can be generated on a catalytic reaction, and the inhibition rate of the reagent on the L-tyrosinase activity is evaluated by measuring the absorbance at 475nm before and after the reagent is added.
2. Preparation of the experiment
1) PBS phosphate buffer (pH 6.8): dissolving 17.91g of dodecahydrate disodium hydrogen phosphate in distilled water, and dissolving in 500 mL; dissolving 7.8g of dihydrate sodium dihydrogen phosphate in distilled water, and dissolving in 500 mL; the two solutions, 92.6mL and 107.4mL, were combined to 200mL of PBS phosphate buffer, pH 6.8.
2)0.1mol/L hydrochloric acid solution: 0.862mL of HCl solution with the HCl content of 36% -38% is used, and the volume is fixed to 100mL by distilled water.
3) 0.05% L-tyrosine solution: 0.05g L-tyrosine was dissolved in 35mL of 0.1mol/L HCl solution, and then 65mL of PBS phosphate buffer (pH6.8) was added thereto to make 100 mL.
4) Tyrosinase solution: diluting the tyrosinase powder with PBS buffer solution to obtain tyrosinase solution with enzyme activity of 100U/mL.
3. Experimental procedure
1) After the C2 pipe is well prepared and shaken up, the mixture is heated in a water bath kettle at 37 ℃ for 10min, and the zero setting is carried out under the wavelength of 475 nm.
2) Mixing the solution in a C1 tube, shaking, performing water bath at 37 ℃ for 10min, adding 1ml of tyrosinase, continuing the water bath for 10min, and determining the absorbance value of C1.
3) The absorbance values of T1 were determined by zeroing with T2 in the same manner as in 1) and 2).
4) And calculating the activity inhibition rate T (%) of the fermentation stock solution sample on the tyrosinase.
TABLE 5 tyrosinase inhibition ratio test reagent proportioning table
Numbering | L-tyrosine | Sample (I) | PBS | Tyrosinase enzyme | Total volume |
C1 | 2mL | —— | 4mL | 1mL | 7ml |
C2 | 2mL | —— | 5ml | —— | 7ml |
T1 | 2ml | 2mL | 2mL | 1mL | 7ml |
T2 | 2ml | 2ml | 3ml | —— | 7ml |
4. Data processing
The formula: t (%) - (C1-T1)/C1 × 100%. The results are shown in Table 6, and the data in the table show that the fomes fomentarius and the pearl are fermented, and the two have synergistic effect, so that the whitening performance of the fermented product is remarkably improved.
TABLE 6 tyrosinase inhibition test results
Finally, it is further noted that, in the present disclosure, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the phrase "comprising an … …" does not exclude the presence of other identical elements in a process, method, article, or apparatus that comprises the element.
While the disclosure has been disclosed above by the description of specific embodiments thereof, it should be understood that various modifications, improvements or equivalents of the disclosure may be devised by those skilled in the art within the spirit and scope of the appended claims. Such modifications, improvements and equivalents are intended to be included within the scope of the present disclosure as claimed.
Claims (10)
1. A preparation method of fomes fomentarius fermentation product is characterized by comprising the following steps:
step one, activating, purifying and carrying out enlarged culture on fomes fomentarius to obtain seed liquid;
inoculating the seed liquid to a fermentation substrate for fermentation culture treatment to obtain fermentation liquid; the fermentation substrate is potato homogenate;
and step three, performing separation treatment and sterilization treatment on the fermentation liquor to obtain supernatant.
2. The method of preparing fomes fomentarius ferment as claimed in claim 1, wherein the potato homogenate is obtained by homogenizing and dissolving fresh cut potatoes in water by a homogenizer, wherein the content of the potatoes is 1 to 5 wt%.
3. The method for producing a fomes fomentarius fermented product according to claim 1 or 2, wherein the potato homogenate further comprises 0.3 wt% of monopotassium phosphate, 0.15 wt% of magnesium sulfate, 0.05 wt% of glucose, and 0.2 wt% of soybean peptide.
4. The method for preparing fomes fomentarius fermented product according to any one of claims 1 to 3, wherein pearl powder is further added to the fermentation substrate; the content of the pearl powder is 1-10 wt% of the potato homogenate; preferably 1 to 5 wt%.
5. The method for producing a fomes fomentarius fermented product according to any one of claims 1 to 4, wherein in the first step, the hypha volume percentage of the seed liquid is 80% or more.
6. The method for preparing fomes fomentarius ferment according to any one of claims 1 to 5, wherein in the second step, the volume ratio of the seed solution to the fermentation substrate is 1% to 10%.
7. The method for preparing fomes fomentarius ferment according to any one of claims 1 to 6, wherein in the second step, the temperature of the fermentation culture treatment is 25 to 35 ℃ and the time is 48 to 96 hours; preferably, the fermentation culture treatment is carried out in a shaker at a rotation speed of 150r/min to 200 r/min.
8. The method for producing a fomes fomentarius ferment according to any one of claims 1 to 7, wherein the separation treatment employs a centrifugation method; preferably, the centrifugal speed is 4500r/min-5500r/min, and the centrifugal time is 10min-20 min.
9. The method for producing fomes fomentarius ferment according to any one of claims 1 to 8, wherein the fomes fomentarius is selected from at least one of: CGMCC5.1494, CGMCC 5.983, GCMCC5.96 and GCMCC 5.913.
10. A fomes fomentarius fermented product, which is produced by the production method according to any one of claims 1 to 9; the fomes fomentarius fermentation product is fomes fomentarius fermentation liquor and dry powder thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210049751.7A CN114699343B (en) | 2022-01-17 | 2022-01-17 | Phellinus linteus fermentation product and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210049751.7A CN114699343B (en) | 2022-01-17 | 2022-01-17 | Phellinus linteus fermentation product and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114699343A true CN114699343A (en) | 2022-07-05 |
CN114699343B CN114699343B (en) | 2024-03-01 |
Family
ID=82166795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210049751.7A Active CN114699343B (en) | 2022-01-17 | 2022-01-17 | Phellinus linteus fermentation product and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114699343B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN119074653A (en) * | 2024-09-13 | 2024-12-06 | 湖北中珠制药有限公司 | Pearl dressing with bactericidal, anti-inflammatory and repairing functions and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1880445A (en) * | 2006-03-31 | 2006-12-20 | 浙江大学 | Tinder fungus and process for deep liquid fermentation preparation of tinder fungus |
KR100931526B1 (en) * | 2009-09-11 | 2009-12-14 | 이성호 | Fermented foods using the seven mycelium mushroom mycelium and its manufacturing method |
CN107523507A (en) * | 2017-09-04 | 2017-12-29 | 北方民族大学 | A kind of culture medium and its cultural method of tinder fungus submerged fermentation |
CN112574893A (en) * | 2020-12-16 | 2021-03-30 | 广东省微生物研究所(广东省微生物分析检测中心) | Phellinus baumii, and preparation method and application of fermentation product thereof |
-
2022
- 2022-01-17 CN CN202210049751.7A patent/CN114699343B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1880445A (en) * | 2006-03-31 | 2006-12-20 | 浙江大学 | Tinder fungus and process for deep liquid fermentation preparation of tinder fungus |
KR100931526B1 (en) * | 2009-09-11 | 2009-12-14 | 이성호 | Fermented foods using the seven mycelium mushroom mycelium and its manufacturing method |
CN107523507A (en) * | 2017-09-04 | 2017-12-29 | 北方民族大学 | A kind of culture medium and its cultural method of tinder fungus submerged fermentation |
CN112574893A (en) * | 2020-12-16 | 2021-03-30 | 广东省微生物研究所(广东省微生物分析检测中心) | Phellinus baumii, and preparation method and application of fermentation product thereof |
Non-Patent Citations (1)
Title |
---|
崔驰浩, 等: "木蹄层孔菌液体发酵工艺条件优化", 中国食用菌, vol. 39, no. 7, pages 26 - 31 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN119074653A (en) * | 2024-09-13 | 2024-12-06 | 湖北中珠制药有限公司 | Pearl dressing with bactericidal, anti-inflammatory and repairing functions and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114699343B (en) | 2024-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109939027B (en) | Method for preparing ergothioneine-containing cosmetic stock solution by fermenting hericium erinaceus | |
CN113337545B (en) | Schizophyllum commune fermentation product, preparation method thereof, skin care product and schizophyllum commune culture medium | |
EP1918363B1 (en) | Strain of turkey tail mushroom, extract from the same, and use of the same | |
CN103263448B (en) | Fermentation bacteria used for fermentation pretreatment to improve extraction of Ginkgo biloba L. leaf flavone and application | |
CN109694886B (en) | Green tea fermentation filtrate and preparation method and application thereof | |
CN113367191B (en) | Lactobacillus paracasei K56 for resisting oxidation and regulating blood pressure and application thereof | |
CN108887673B (en) | Preparation method of wild papaya enzyme rich in superoxide dismutase SOD | |
CN113349254B (en) | Antioxidant and blood pressure regulating lactobacillus paracasei ET-22 and application thereof | |
WO2021158179A1 (en) | SCHIZOPHYLLUM COMMUNE STRAIN PLNP13 AND β-GLUCAN OBTAINED FROM CO-CULTURING THE STRAIN WITH GANODERMA LUCIDUM | |
CN108530549B (en) | Method for extracting polysaccharide from ganoderma lucidum mycelia | |
KR100787633B1 (en) | Improvement of liver function and hangover tea and its manufacturing method | |
CN112691125B (en) | Pharmaceutical composition for whitening or resisting aging, preparation method thereof and skin care product | |
CN113350383A (en) | Bifidobacterium lactis BL-99 capable of resisting oxidation and regulating blood pressure and application thereof | |
CN115572738A (en) | Dendrobium officinale fermentation liquor with anti-inflammatory, relieving and repairing effects as well as preparation method and application thereof | |
CN113842347A (en) | Composition of Mohong rose Ganoderma lucidum fermented product and Mohong rose fermented product after enzymatic hydrolysis with anti-aging and whitening activities | |
CN114699343B (en) | Phellinus linteus fermentation product and preparation method thereof | |
CN112618610A (en) | Papaya fermented juice and use thereof for improving skin condition | |
CN113842341B (en) | Roselle fermentation product and preparation method and application thereof | |
CN111544352B (en) | Tremella-ganoderma lucidum composite fermentation product, cosmetic composition with anti-aging effect and preparation method and application thereof | |
CN114262721A (en) | Fermentation process of ginger extract, fermentation product and application thereof | |
CN110833187A (en) | Enzyme stock solution and preparation method thereof | |
CN113208976A (en) | Skin-firming and nourishing ganoderma lucidum composite fermentation product and preparation method and application thereof | |
CN111494269A (en) | Grape fermentation raw pulp and preparation method and application thereof | |
CN114533633B (en) | Phellinus baumii ferment and preparation method thereof | |
JP2012017337A (en) | Composition for alcohol metabolism promotion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |